SciSparc Ltd. is a biotechnology company focused on the development and commercialization of innovative treatments for various medical conditions, particularly those related to the central nervous system. The company is engaged in advancing therapies that aim to address significant unmet needs, utilizing its proprietary platform to explore and enhance the effectiveness of cannabinoid-based treatments. Through its research and development efforts, SciSparc aims to create novel solutions that enhance patient outcomes and improve quality of life in underserved therapeutic areas.
SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel. The Israeli specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system enrolled the first patient in its clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder in March.
SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milestones of $3M in cash plus royalties.
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
Shares of Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation (NASDAQ: WFTC) and Macatawa Bank announced that they have entered into a definiti
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
The first patient has been enrolled in SciSparc Ltd.'s clinical trial evaluating the effectiveness and safety of their CBD-based drug for treating children with autism spectrum disorder, marking a significant advancement in ASD treatment. CEO Oz Adler expressed excitement about this milestone, highlighting the potential impact of the SCI-210 therapy in managing ASD symptoms. The company plans to enroll 60 participants aged 5 to 18 for a 20-week trial, comparing SCI-210 therapy with standard CBD treatment, in collaboration with the National Autism Research Center. Partnering with Tikun Olam Cannbit Pharmaceuticals Ltd., SciSparc aims to bring SCI-210 to market in Israel initially, with global distribution pending regulatory approvals. Additionally, the company achieved patent approvals in Canada for their opioid and n-acylethanolamine combination for pain management, as well as validation for their core technology patent in 15 European countries, demonstrating their commitment to advancing cannabinoid-based therapeutics.
